Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, ...

However, Novo Nordisk's chief rival in the weight loss space shouldn't be slept on. Eli Lilly (LLY -3.37%), the developer of Mounjaro, has proven that it can compete with Novo Nordisk at a high level.

But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the active ingredient in Mounjaro and Zepbound, from its shortage list.

Shares in Novo Nordisk fell as much as 30% after it slashed sales and profits forecasts for the second time this year amid ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...

Eli Lilly filed a complaint with the U.S. International Trade Commission on Thursday to block companies from importing and selling cheaper versions of its blockbuster drug Mounjaro online ...